赖氨酸
生物
溶解循环
抗生素
噬菌体
梭菌纲
微生物学
抗生素耐药性
艰难梭菌
病毒学
遗传学
大肠杆菌
病毒
基因
作者
Shakhinur Islam Mondal,Lorraine A. Draper,R. Paul Ross,Colin Hill
出处
期刊:Gut microbes
[Informa]
日期:2020-09-28
卷期号:12 (1): 1813533-1813533
被引量:26
标识
DOI:10.1080/19490976.2020.1813533
摘要
Clostridioides difficile is the leading cause of health-care-associated infection throughout the developed world and contributes significantly to patient morbidity and mortality. Typically, antibiotics are used for the primary treatment of C. difficile infections (CDIs), but they are not universally effective for all ribotypes and can result in antibiotic resistance and recurrent infection, while also disrupting the microbiota. Novel targeted therapeutics are urgently needed to combat CDI. Bacteriophage-derived endolysins are required to disrupt the bacterial cell wall of their target bacteria and are possible alternatives to antibiotics. These lytic proteins could potentially replace or augment antibiotics in CDI treatment. We discuss candidate therapeutic lysins derived from phages/prophages of C. difficile and their potential as antimicrobials against CDI. Additionally, we review the antibacterial potential of some recently identified homologues of C. difficile endolysins. Finally, the challenges of endolysins are considered with respect to the development of novel lysin-based therapies.
科研通智能强力驱动
Strongly Powered by AbleSci AI